Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onivyde combinations in children and young adults with recurrent solid tumors and Ewing sarcoma
2021-003570-31Phase 2
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Jul 2021
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in Ewing sarcoma and Non-hematologic malignancy comparing Onivyde + talazoparib with Onivyde + temozolomide (2 arms). Primary endpoint: First cycle dose-limiting toxicities.
02
Drugs
irinotecantalazoparibtemozolomide
03
Conditions
Ewing sarcomaNon-hematologic malignancy
Beyond the preview
Go deeper on 2021-003570-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003570-31.